Pertuzumab usage and dosage

The initial dose of Pertuzumab is 840 mg as an intravenous infusion over 60 minutes, followed by 420 mg as an intravenous infusion over 30 to 60 minutes every 3 weeks. When administered with pertuzumab, the recommended initial dose of trastuzumab is 8 mg/kg as an intravenous infusion over 90 minutes, followed by 6 mg/kg as an intravenous infusion over 30 to 90 minutes every 3 weeks. The recommended initial dose of trastuzumab hyaluronidase-oysk is 600 mg/10,000 units, administered subcutaneously every three weeks for approximately 2-5 minutes, regardless of patient weight.

When administered with pertuzumab for the treatment of metastatic breast cancer (MBC), the recommended initial dose of docetaxel is 75 mg/m2 administered by intravenous infusion. If the initial dose is well tolerated, the dose may be increased to 100 mg/m2 every 3 weeks. When administered as part of one of the treatment regimens for early-stage breast cancer, administered every 3 weeks for 3-6 cycles, patients should continue to receive pertuzumab and trastuzumab or trastuzumab hyaluronidase-oysk after surgery to complete 1 year of treatment (up to 18 cycles). When used as adjuvant therapy for breast cancer, pertuzumab should be administered in combination with trastuzumab or trastuzumab hyaluronidase-oysk every 3 weeks for 1 year (up to 18 cycles) or until disease recurrence or uncontrollable toxicity, as part of a complete regimen for early-stage breast cancer including standard anthracycline and/or taxane chemotherapy as given in the appendix.

Pertuzumab is a strictly controlled drug. The original drug has been marketed in China and has entered the ranks of medical insurance, but it is only reimbursed for patients who meet the indications. The price of each box may be more than more than 5,000 yuan, and the price of the Hong Kong version may be more than 20,000 yuan (the price may fluctuate due to exchange rates). The price of each box of the European version of Pertuzumab's original drug marketed overseas may be more than 10,000 yuan, and the price of each box of the Turkish version may be more than 6,000 yuan (the price may fluctuate due to exchange rates). The ingredients of the domestic and foreign original drugs are basically the same, and there are currently no generic versions of Pertuzumab on the market.